Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$2.0M
Filings
33
Firms Hired
2
Active Period
2021–2024
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Tax Relief for American Families and Workers Act of 2024
2024 · third_quarter · Firm: IGM BIOSCIENCES, INC.
H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Client expense: $50,000 · Firm income: —
Matched citations: H.R.7024
H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Client expense: $50,000 · Firm income: —
Matched citations: H.R.7085
Prohibiting Foreign Access to American Genetic Information Act of 2024
2024 · third_quarter · Firm: IGM BIOSCIENCES, INC.
H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Client expense: $50,000 · Firm income: —
Matched citations: S.3558
Tax Relief for American Families and Workers Act of 2024
2024 · second_quarter · Firm: IGM BIOSCIENCES, INC.
H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Client expense: $80,000 · Firm income: —
Matched citations: H.R.7024
H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Client expense: $80,000 · Firm income: —
Matched citations: H.R.7085
Prohibiting Foreign Access to American Genetic Information Act of 2024
2024 · second_quarter · Firm: IGM BIOSCIENCES, INC.
H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Client expense: $80,000 · Firm income: —
Matched citations: S.3558
Tax Relief for American Families and Workers Act of 2024
2024 · first_quarter · Firm: IGM BIOSCIENCES, INC.
Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Client expense: $110,000 · Firm income: —
Matched citations: H.R.7024
Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Client expense: $110,000 · Firm income: —
Matched citations: H.R.7085
Prohibiting Foreign Access to American Genetic Information Act of 2024
2024 · first_quarter · Firm: IGM BIOSCIENCES, INC.
Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations H.R.7085 - BIOSECURE Act S.3558 - A bill to prohibit contracting with certain biotechnology providers, and for other purposes (Senate BIOSECURE Act) H.R.7024 - Tax Relief for American Families and Workers Act
Client expense: $110,000 · Firm income: —
Matched citations: S.3558
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: $240,000 · Firm income: —
Matched citations: H.R.3932
Fiscal Responsibility Act of 2023
2023 · fourth_quarter · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: $240,000 · Firm income: —
Matched citations: H.R.3746
Preparing for All Hazards and Pathogens Reauthorization Act
2023 · fourth_quarter · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: $240,000 · Firm income: —
Matched citations: H.R.4421
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: $240,000 · Firm income: —
Matched citations: S.2076
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: $240,000 · Firm income: —
Matched citations: S.3799
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: $230,000 · Firm income: —
Matched citations: H.R.3932
Fiscal Responsibility Act of 2023
2023 · third_quarter · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: $230,000 · Firm income: —
Matched citations: H.R.3746
Preparing for All Hazards and Pathogens Reauthorization Act
2023 · third_quarter · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: $230,000 · Firm income: —
Matched citations: H.R.4421
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: $230,000 · Firm income: —
Matched citations: S.2076
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: $230,000 · Firm income: —
Matched citations: S.3799
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: $230,000 · Firm income: —
Matched citations: H.R.3932
Fiscal Responsibility Act of 2023
2023 · second_quarter · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: $230,000 · Firm income: —
Matched citations: H.R.3746
Preparing for All Hazards and Pathogens Reauthorization Act
2023 · second_quarter · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: $230,000 · Firm income: —
Matched citations: H.R.4421
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: $230,000 · Firm income: —
Matched citations: S.2076
COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: $230,000 · Firm income: —
Matched citations: S.3799
Consolidated Appropriations Act, 2023
2023 · first_quarter · Firm: IGM BIOSCIENCES, INC.
COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 H.R.2617 - Consolidated Appropriations Act, 2023 FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan
Client expense: $230,000 · Firm income: —
Matched citations: H.R.2617
Source: Senate LDA